Navigation Links
Drug shows promise for the first time against metastatic melanoma of the eye
Date:6/19/2014

NEW YORK, NY (June 19, 2014) For the first time, a therapy has been found that can delay progression of metastatic uveal melanoma, a rare and deadly form of melanoma of the eye.

Results from a multicenter clinical trial show that a new drug called selumetinib increases progression-free survival, the length of time during and after treatment that a patient with metastases lives with the disease without it progressing. The findings were published today in the online edition of JAMA, the Journal of the American Medical Association.

"Although the effects of the drug were modest, we now know that we can influence the course of the disease, and we expect to build on this success with other drugs, including some already in development," said senior author, Gary K. Schwartz, MD, professor of medicine and chief of hematology/oncology at NewYork-Presbyterian/Columbia University Medical Center and associate director of its Herbert Irving Comprehensive Cancer Center. (At the time of the trial, Dr. Schwartz was chief of the melanoma and sarcoma service at Memorial Sloan Kettering Cancer Center in New York.)

Uveal melanoma is a cancer of the iris, ciliary body, or choroidstructures in the eye collectively known as the uvea. Uveal melanoma (which is biologically distinct from skin melanoma) arises from the uvea's melanocytes, the pigment cells that give the eye its color. Once the disease has spreadmost metastases appear in the liverexisting treatments are largely ineffective. About 1,500 cases of uveal melanoma occur in the United States each year, usually among older adults. The median survival rate for patients with metastatic uveal melanoma is 12 months.

Several years ago, researchers found that 80 percent of patients with uveal melanoma had mutations to GNAQ or GNA11, genes that activate signals in the mitogen-activated protein kinase (MAPK) pathway. Dr. Schwartz and others subsequently demonstrated that inhibition of M
'/>"/>

Contact: Karin Eskenazi
Ket2116@columbia.edu
Columbia University Medical Center
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. BU-lead study shows surprising spread of spring leaf-out times
2. Study shows race a factor in mortality in heart attack patients on anti-clotting drug
3. Arctic warming linked to fewer European and US cold weather extremes, new study shows
4. New study shows that oatmeal can help you feel full longer
5. Saving trees in tropics could cut emissions by one-fifth, study shows
6. Doing more means changing less when it comes to gene response, new study shows
7. Research shows compassion and euthanasia dont always jibe
8. Study shows impact of tart cherries on inflammation and oxidative stress after cycling
9. Marijuana shows potential in treating autoimmune disease
10. Study shows tale of 2 prognoses in pediatric brain tumor, pilocytic astrocytoma
11. ALK, ROS1 and now NTRK1: Study shows prevalence of new genetic driver in lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug shows promise for the first time against metastatic melanoma of the eye
(Date:4/9/2015)... SAN JOSE, Calif. , April 9, 2015 /PRNewswire/ ... of human interface solutions, announced today that it will ... 2015 on Thursday, April 23, 2015, after the close ... call for analysts and investors at 2:00 p.m. PT ... information.    To participate on the live ...
(Date:4/2/2015)... 2015 At its 2015 ACMG Annual Clinical ... , the American College of Medical Genetics and Genomics ... its Board.  Members of the ACMG Board of Directors ... and advancing its policies and programs. ACMG is the ... "It,s an eventful time in medical genetics and genomics.  ...
(Date:4/1/2015)... --  Medisafe ™, the leading global medication management platform ... and Android smartphones and tablets, announces today ... to allow patients to track and correlate their adherence ... will be able to visualize in real-time how taking ... as glucose levels and blood pressure. "Patients ...
Breaking Biology News(10 mins):Synaptics to Report Third Quarter Results on April 23 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
... study has found that some bird species in the desert ... by widespread fire through their habitat. In fact, the Baylor ... of the habitat that is formed after a fire is ... that three specific bird species in the Chihuahuan Desert ...
... NC The shape of a hummingbird,s beak allows for a ... in a mere fraction of a second with greater speed and ... new study in a forthcoming issue of Journal of Theoretical ... but hummingbirds can,t live on nectar alone. To get enough protein ...
... new journal in systematic and biology of fungi (including lichens) was launched ... Dr Thorsten Lumbsch from The Field Museum, Chicago assisted by an authoritative ... is free to read, download, print, and distribute. MycoKeys ... and PhytoKeys . It is more than ...
Cached Biology News:Study finds some desert birds less affected by wildfires and climate change 2Hummingbirds catch flying bugs with the help of fast-closing beaks 2Pensoft Publishers launch a new mycological open-access journal 2Pensoft Publishers launch a new mycological open-access journal 3
(Date:4/30/2015)... CA (PRWEB) April 30, 2015 SureClinical, ... that Julie I. Morris has joined SureClinical’s executive team ... an experienced biotech and technology executive with over 25 ... Fortune 500 companies. , Ms. Morris joins SureClinical ... biotech company. She was CFO of MBI from its ...
(Date:4/29/2015)... 2015 According to a new ... Product (Portable & Non-Portable), Component (Accelerometer, Proximity Probe, ... Metal & Mining, & Others), & Geography - ... expected to reach $1,453.76 Million by 2020, at ... data tables and 92 figures spread through 205 ...
(Date:4/29/2015)... , April 29, 2015   Doximity , ... of all US doctors as members, announced a new, ... — "Apply Using Doximity." With one click, all US ... a curriculum vitae (CV) for an open job opportunity, ... directly. Eighty seven percent of physicians are ...
(Date:4/29/2015)... Poway, CA (PRWEB) April 29, 2015 ... proud to announce that its regenerative stem cell therapy ... founded in 2002, seeking to discover a successful treatment ... ligaments. , In 2003 VetStem signed a worldwide exclusive ... veterinary application, and the first horse was treated in ...
Breaking Biology Technology:Julie I. Morris Joins SureClinical as Chief Financial Officer 2Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 2Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 3Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 4Doximity Offering Hospitals Easy, Efficient Physician Application Tool 2VetStem Biopharma -Regenerative Cell Therapy has processed over 11,000 samples 2
... For NDA and to Complete Current Phase 3 Trial ... BETHESDA, Md., June 23 Spherix Incorporated (Nasdaq: ... therapy, and a provider of technical and regulatory consulting ... announced that it has received its first full-scale production ...
... Diagnostic Industry Magazine,s 30 Years, 30 Devices Special Issue Commends B. ... Medical Device and Diagnostic Industry has recognized three medical devices ... infusion therapy and pain management as well as a pioneer in ... the most influential medical devices of the last 30 years. ...
... Human Protein Atlas, available exclusively through Sigma-Aldrich, bring the portfolio ... , ST. LOUIS, June 23 Sigma-Aldrich (Nasdaq: ... additions to its Prestige Antibodies(R) powered by Atlas Antibodies product ... of highly validated antibodies to over 6,100. Developed by the ...
Cached Biology Technology:Spherix Announces Full-Scale Production of Pharmaceutical Tagatose 2Spherix Announces Full-Scale Production of Pharmaceutical Tagatose 3Spherix Announces Full-Scale Production of Pharmaceutical Tagatose 4B. Braun Medical Inc. Recognized by Industry for Manufacturing Influential Medical Devices 2B. Braun Medical Inc. Recognized by Industry for Manufacturing Influential Medical Devices 3B. Braun Medical Inc. Recognized by Industry for Manufacturing Influential Medical Devices 4Sigma-Aldrich and Atlas Antibodies Announce 2,300 New, Highly Validated Prestige Antibodies(RM) 2Sigma-Aldrich and Atlas Antibodies Announce 2,300 New, Highly Validated Prestige Antibodies(RM) 3Sigma-Aldrich and Atlas Antibodies Announce 2,300 New, Highly Validated Prestige Antibodies(RM) 4
... The Amplifluor UniPrimer-fluorescein is a hairpin ... transfer pair (fluorescein and non-fluorescent quencher) ... The UniPrimer is identical to ... Universal Detection System (S7901) and is ...
...
Mouse monoclonal antibody raised against a partial recombinant EBI3. NCBI Entrez Gene ID = EBI3...
... Model AS-2055 and AS-2057 are fully automatic ... highest possible level of precision. Sampling flexibility ... positions (microplate) for,laboratory automation and combinatorial chemistry. ... micro-vials or the standard rack for 50 ...
Biology Products: